Discounting in the evaluation of the cost-effectiveness of a vaccination programme: A critical review

Vaccine

Volumn 33, Issue 32, 2015, Pages 3788-3794

  Jit, Mark ^a,b   Mibei, Walter ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Cost effectiveness; Discounting; Vaccination

Indexed keywords

CHICKENPOX VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; SMALLPOX VACCINE; VACCINE; WART VIRUS VACCINE;

COST EFFECTIVENESS ANALYSIS; DISCOUNTING; ECONOMIC DEVELOPMENT; ECONOMIC EVALUATION; HEALTH PROGRAM; HUMAN; INFLUENZA VACCINATION; INVESTMENT; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TIME; VACCINATION; COST BENEFIT ANALYSIS; ECONOMICS; PREVENTIVE HEALTH SERVICE;

COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION PROGRAMS; VACCINATION;

EID: 84937512954     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.06.084     Document Type: Review

References (71)

1. Kim S-Y., Goldie S.J. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 2008, 26:191-215.
2. Krahn M., Gafni A. Discounting in the economic evaluation of health care interventions. Med Care 1993, 31:403-418.
3. Frederick S., Loewenstein G., O'Donoghue T. Time discounting and time preference a critical review. J Econ Lit 2002, 40:351-401. 10.1257/002205102320161311.
4. Brouwer W.B.F., Niessen L.W., Postma M.J., Rutten F.F.H. Need for differential discounting of costs and health effects in cost effectiveness analyses. Br Med J 2005, 331:446-448. 10.1136/bmj.331.7514.446.
5. Brouwer W., van Hout B., Rutten F. A fair approach to discounting future effects: taking a societal perspective. J Health Serv Res Policy 2000, 5:114-118.
6. Tinghög G. Discounting, preferences, and paternalism in cost-effectiveness analysis. Health Care Anal 2012, 20:297-318. 10.1007/s10728-011-0188-6.
7. Gravelle H., Smith D. Discounting for health effects in cost-benefit and cost-effectiveness analysis. Health Econ 2001, 10:587-599. 10.1002/hec.618.
8. Lipscomb J. Time preference for health in cost-effectiveness analysis. Med Care 1989, 27:S233-S253.
9. Claxton K., Paulden M., Gravelle H., Brouwer W., Culyer A.J. Discounting and decision making in the economic evaluation of health-care technologies. Health Econ 2011, 20:2-15. 10.1002/hec.1612.
10. Van Hout B.A. Discounting costs and effects: a reconsideration. Health Econ 1998, 7:581-594.
11. Tasset A., Nguyen V.H., Wood S., Amazian K. Discounting: technical issues in economic evaluations of vaccination. Vaccine 1999, 17(Suppl 3):S75-S80.
12. Beutels P., Edmunds W.J., Antoñanzas F., De Wit G.A., Evans D., Feilden R., et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics 2002, 20:1-7.
13. Bos J.M., Beutels P., Annemans L., Postma M.J. Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases. Pharmacoeconomics 2004, 22:1171-1179.
14. Bos J.M., Postma M.J., Annemans L. Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics 2005, 23:639-649.
15. Westra T.A., Parouty M., Brouwer W.B., Beutels P.H., Rogoza R.M., Rozenbaum M.H., et al. On discounting of health gains from human papillomavirus vaccination: effects of different approaches. Value Health 2012, 15:562-567. 10.1016/j.jval.2012.01.005.
16. Drummond M., Chevat C., Lothgren M. Do we fully understand the economic value of vaccines?. Vaccine 2007, 25:5945-5957. 10.1016/j.vaccine.2007.04.070.
17. Brisson M., Van de Velde N., Boily M-C. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009, 12:343-351. 10.1159/000214924.
18. Beutels P., Thiry N., Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination-a review (2002-2006). Vaccine 2007, 25:1355-1367.
19. Van de Vooren K., Duranti S., Curto A., Garattini L. Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies. Pharmacoeconomics 2014, 32:29-45. 10.1007/s40273-013-0113-y.
20. Bilcke J., Beutels P. Reviewing the cost-effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources. Pharmacoeconomics 2009, 27:281-297.
21. Griffiths U.K., Miners A. Economic evaluations of Haemophilus influenzae type b vaccine: systematic review of the literature. Expert Rev Pharmacoecon Outcomes Res 2009, 9:333-346. 10.1586/erp.09.38.
22. Newall A.T., Jit M., Beutels P. Economic evaluations of childhood influenza vaccination: a critical review. Pharmacoeconomics 2012, 30:647-660.
23. Kuhlmann A., Theidel U., Pletz M.W., von der Schulenburg J.M. Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany. Health Econ Rev 2012, 2. 10.1186/2191-1991-2-4.
24. Talbird S.E., Taylor T.N., Knoll S., Frostad C.R., García Martí S. Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. Vaccine 2010, 28(Suppl 6):G23-G29. 10.1016/j.vaccine.2010.06.016.
25. Carlin J.B., Jackson T., Lane L., Bishop R.F., Barnes G.L. Cost effectiveness of rotavirus vaccination in Australia. Aust N Z J Public Health 1999, 23:611-616.
26. Duke T. Haemophilus influenzae type b meningitis: how much better is prevention than cure?. P N G Med J 2002, 45:213-218.
27. Moore D., Bigham M., Patrick D. Modelling the costs and effects of a universal infant immunization program using conjugated pneumococcal vaccine in British Columbia. Can Commun Dis Rep 2003, 29:97-104.
28. Treasury H.M. The green book: appraisal and evaluation in central government 2011, TSO, London.
29. Bergeron C., Largeron N., McAllister R., Mathevet P., Remy V. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care 2008, 24:10-19. 10.1017/S0266462307080026.
30. Fenner F., Henderson D., Arita I., Jeek Z., Ladnyi I. Smallpox and its eradication 1988, World Health Organisation, Geneva.
31. Van Hoek A.J., Melegaro A., Gay N., Bilcke J., Edmunds W.J. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. Vaccine 2012, 30:1225-1234. 10.1016/j.vaccine.2011.11.026.
32. Baguelin M., Flasche S., Camacho A., Demiris N., Miller E., Edmunds W.J. Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study. PLoS Med 2013, 10:e1001527. 10.1371/journal.pmed.1001527.
33. Ramsey F.P. A mathematical theory of saving. Econ J 1928, 38:543-559. 10.2307/2224098.
34. Samuelson P.A. A note on measurement of utility. Rev Econ Stud 1937, 4:155. 10.2307/2967612.
35. Tan-Torres Edejer T., Baltussen R., Adam T., Hutubessy R., Acharya A., Evans D.B., et al. Making choices in health: WHO guide to cost-effectiveness analysis 2003, World Health Organisation, Geneva.
36. Lipscomb J., Weinstein M.C., Torrance G.W. Time preference. In: Gold M, Siegel J, Russel L, Weinstein M, editors. Cost-effectiveness Heal. Med 1996, p, Oxford University Press, New York, NY, 214-46.
37. Mathes T., Jacobs E., Morfeld J-C., Pieper D. Methods of international health technology assessment agencies for economic evaluations-a comparative analysis. BMC Health Serv Res 2013, 13:371. 10.1186/1472-6963-13-371.
38. Walker D.G., Hutubessy R., Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine 2010, 28:2356-2359. 10.1016/j.vaccine.2009.06.035.
39. Claxton K., Sculpher M., Culyer A., McCabe C., Briggs A., Akehurst R., et al. Discounting and cost-effectiveness in NICE-stepping back to sort out a confusion. Health Econ 2006, 15:1-4. 10.1002/hec.1081.
40. National Institute for Health and Care Excellence Guide to the methods of technology appraisal 2013.
41. O'Mahony J.F., Paulden M. NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified. Value Health 2014, 17:493-496. 10.1016/j.jval.2013.02.014.
42. Bonneux L., Birnie E. The discount rate in the economic evaluation of prevention: a thought experiment. J Epidemiol Commun Health 2001, 55:123-125. 10.1136/jech.55.2.123.
43. McKie J., Richardson J. The rule of rescue. Soc Sci Med 2003, 56:2407-2419. 10.1016/S0277-9536(02)00244-7.
44. National Institute for Health and Care Excellence Social value judgements: principles for the development of NICE guidance 2008.
45. Weinstein M.C., Stason W.B. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977, 296:716-721. 10.1056/NEJM197703312961304.
46. Williams A. Welfare economics and health status management 1981, 123-132. In: van der Gaag J, Perlman M, editors. Heal. Econ. Heal. Econ., Amsterdam: North Holland Publishing.
47. Keeler E.B., Cretin S. Discounting of life-saving and other nonmonetary effects. Manage Sci 1983, 29:300-306. 10.1287/mnsc.29.3.300.
48. Postma M.J., Westra T.A., Quilici S., Largeron N. Economic evaluation of vaccines: specificities and future challenges illustrated by recent European examples. Expert Rev Vaccines 2013, 12:555-565. 10.1586/erv.13.36.
49. Cohen B.J. Discounting in cost-utility analysis of healthcare interventions: reassessing current practice. Pharmacoeconomics 2003, 21:75-87.
50. Lazaro A., Barberan R., Rubio E. The economic evaluation of health programmes: why discount health consequences more than monetary consequences?. Appl Econ 2002, 34:339-350. 10.1080/00036840110043758.
51. Cairns J.A. Valuing future benefits. Health Econ 1994, 3:221-229.
52. Rawls J. A theory of justice 1999, Harvard University Press. rev. ed.
53. Murray C.J., Acharya A.K. Understanding DALYs. J Health Econ 1997, 16:3-30. 10.1016/S0167-6296(97)00004-0.
54. Parfit D. Reasons and Persons 1984, Oxford University Press.
55. Schelling T.C. Intergenerational discounting. Ene Policy 1995, 23:395-401. 10.1016/0301-4215(95)90164-3.
56. Sen A. Approaches to the choice of discount rates for social benefit-cost analysis. Discounting for time and risk in energy policy, Resources for the future 1982, R.C. Lind (Ed.).
57. Harvey C.M. The reasonableness of non-constant discounting. J Public Econ 1994, 53:31-51. 10.1016/0047-2727(94)90012-4.
58. Loewenstein G., Prelec D. Anomalies in intertemporal choice: evidence and an interpretation. Q J Econ 1992, 107:573-597.
59. Cairns J. Developments in discounting: with special reference to future health events. Resour Energy Econ 2006, 28:282-297. 10.1016/j.reseneeco.2006.02.005.
60. Johannesson M., Johansson P.O. The discounting of lives saved in future generations-some empirical results. Health Econ 1996, 5:329-332. 10.1002/(SICI)1099-1050(199607)5:4<329::AID-HEC213>3.0.CO;2-#.
61. Parouty M.B.Y., Le H.H., Krooshof D., Postma M.J. Differential time preferences for money and quality of life. Pharmacoeconomics 2014, 32:411-419. 10.1007/s40273-013-0124-8.
62. Laibson D. Golden eggs and hyperbolic discounting. Q J Econ 1997, 112:443-478. 10.1162/003355397555253.
63. Fishburn P.C., Rubinstein A. Time preference. Int Econ Rev (Philadelphia) 1982, 23:677-694.
64. Ahlbrecht M., Weber M. An empirical study on intertemporal decision making under risk. Manage Sci 1997, 43:813-826.
65. Bleichrodt H., Johannesson M. Time preference for health: a test of stationarity versus decreasing timing aversion. J Math Psychol 2001, 45:265-282. 10.1006/jmps.2000.1312.
66. Loewenstein G., Prelec D. Negative time preference. Am Econ Rev 1991, 81:347-352. 10.1126/science.151.3712.867-a.
67. Cohen D.R. Utility model of preventive behaviour. J Epidemiol Community Health 1984, 38:61-65. 10.1136/jech.38.1.61.
68. Van Der Pol M.M., Cairns J.A. Negative and zero time preference for health. Health Econ 2000, 9:171-175.
69. Samuelson W., Zeckhauser R. Status quo bias in decision making. J Risk Uncertain 1988, 1:7-59. 10.1007/BF00055564.
70. O'Mahony J.F., de Kok I.M.C.M., van Rosmalen J., Habbema J.D.F., Brouwer W., van Ballegooijen M. Practical implications of differential discounting in cost-effectiveness analyses with varying numbers of cohorts. Value Health 2011, 14:438-442. 10.1016/j.jval.2010.09.009.
71. O'Mahony J.F., Postma M.J., Boersma C., Westra T.A., van Rosmalen J., Jit M. Correcting for multiple future cohorts when applying differential discounting of costs and health effects. Presented at the society for medical decision making 14th biennial European meeting 2012.